South Africa has struggled to secure adequate stock of urgently needed Covid-19 vaccines.
This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer the Biovac Institute (Biovac) is not better positioned to respond to the pandemic.
What then did 17 years of state investment in Biovac get us? As often is the case, the answer is both more nuanced and more interesting than it might appear at first.
Started as a PPP
Until local pharmaceutical company Aspen Pharmacare’s recent announcement that it had secured a contract agreement with Johnson & Johnson (J&J) to fill and finish their Covid-19 vaccines, Biovac was the only vaccine manufacturer in South Africa and one of only a handful of vaccine manufacturers in Africa.